A cascade-activated nanotheranostic platform for MRI-guided hydrogen sulfide therapy and microenvironment remodeling in inflammatory bowel disease
Biomaterials Advances · 2026-09 · 186 · 214941
DOI: 10.1016/j.bioadv.2026.214941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Advances, 2026-09. Verfasst von Wenjing Hou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China; Chongqing Ke…. Hauptthemen laut MEDLINE: Hydrogen Sulfide, Inflammatory Bowel Diseases, Magnetic Resonance Imaging, Theranostic Nanomedicine. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality, Chongqing Medical University.
Abstract (Originalsprache)
Clinical implementation of hydrogen sulfide (H2S) therapy for inflammatory bowel disease (IBD) is hindered by the lack of delivery systems capable of stable, intestine-targeted, and endogenous thiol-independent gas release. To address this, we introduce TB-MnS@S100, a fully synthetic, orally deliverable nanotheranostic platform that decouples H2S release from host biochemistry while enabling real-time imaging. The system comprises a tributyrin-manganese sulfide (TB-MnS) core encapsulated in a pH-responsive Eudragit S100 shell, which remains intact in the upper gastrointestinal tract but dissolves in the alkaline intestinal environment. This platform fully leverages lipases naturally present in vivo-lipase-mediated hydrolysis of tributyrin generates butyrate, whose intracellular metabolism acidifies the local microenvironment, thereby triggering controlled MnS decomposition. This cascade ingeniously exploits endogenous lipase activity to achieve stable and sustained hydrogen sulfide (H2S) release, accompanied by Mn2+ production, providing T1-weighted magnetic resonance imaging (MRI) contrast enhancement without relying on exogenous activators. In a murine model of inflammatory bowel disease induced by dextran sulfate sodium, TB-MnS@S100 achieves synergistic butyrate-H2S therapy, suppressing oxidative stress, downregulating pro-inflammatory cytokines, restoring epithelial tight junction integrity, and rebalancing gut microbiota. The released Mn2+ also enables non-invasive MRI monitoring of inflammation and treatment response, establishing a closed therapeutic-monitoring loop. This work presents an exogenous activator-independent H2S delivery strategy that advances nanotheranostics for IBD by integrating mechanism-guided therapy with real-time imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China; Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, the Second A…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing Municipality
- Chongqing Medical University
Zitieren
APA
Hou, W., Wang, S., Tan, M., & Ran, H. (2026). A cascade-activated nanotheranostic platform for MRI-guided hydrogen sulfide therapy and microenvironment remodeling in inflammatory bowel disease. Biomaterials Advances, 186, 214941. https://doi.org/10.1016/j.bioadv.2026.214941
Vancouver
Hou W, Wang S, Tan M, Ran H. A cascade-activated nanotheranostic platform for MRI-guided hydrogen sulfide therapy and microenvironment remodeling in inflammatory bowel disease. Biomaterials Advances. 2026;186:214941. doi:10.1016/j.bioadv.2026.214941
BibTeX
@article{Hou2026,
author = {Hou, Wenjing and Wang, Siyu and Tan, Mixiao and Ran, Haitao},
title = {A cascade-activated nanotheranostic platform for MRI-guided hydrogen sulfide therapy and microenvironment remodeling in inflammatory bowel disease},
journal = {Biomaterials Advances},
year = {2026},
volume = {186},
pages = {214941},
doi = {10.1016/j.bioadv.2026.214941}
}
EUVIMED